Astaxanthin Added 12 Percent to Male Mouse Lifespan. The Same Program Ran It Again and Got Nothing.
In late 2023 the NIA Interventions Testing Program reported that astaxanthin, the red carotenoid that gives salmon and flamingos their color, extended the median lifespan of male mice by 12 percent. The result came from the most methodologically careful mouse aging program in the world: three independent laboratories, genetically heterogeneous animals, treatment started in middle age, hundreds of mice per arm. Supplement marketing picked the number up within weeks and has not put it down since. What happened next got far less attention. The same program tested astaxanthin again in a later cohort, published the results in GeroScience in 2026, and found no lifespan effect in male or female mice. This is a review of what both cohorts actually reported, why the first result appeared only in males, and how far a 4 milligram capsule sits from the dose the mice were eating.
Key Takeaways: What the Astaxanthin Lifespan Evidence Actually Shows
Astaxanthin is a xanthophyll carotenoid produced by the microalga Haematococcus pluvialis, sold as a dietary supplement at 4 to 12 milligrams per capsule, and studied in humans mostly for exercise recovery, skin appearance and eye fatigue. The NIA Interventions Testing Program reported in GeroScience that astaxanthin extended male UM-HET3 mouse median lifespan by 12 percent at p equals 0.003, with treatment beginning at 12 months of age, alongside meclizine at 8 percent at p equals 0.03. Neither compound affected female lifespan, with p values of 0.64 for astaxanthin and 0.40 for meclizine, and the gains at the 90th percentile were 6 percent for both and did not reach significance at p equals 0.19 and p equals 0.14. The astaxanthin arm contained 156 male and 132 female mice and received a measured dietary average of 1,840 parts per million against a target of 4,000, meaning the delivered dose was about 46 percent of what the program intended. A second Interventions Testing Program report published in GeroScience in 2026, covering eleven compounds including astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate and an atorvastatin-telmisartan combination, found that none of them increased lifespan in male or female mice at the doses and schedules used. Converting 1,840 parts per million of dietary astaxanthin to a human-equivalent dose gives roughly 1,600 milligrams per day for an 80 kilogram adult, which is more than a hundred times a standard 12 milligram capsule and more than three hundred times a 4 milligram one. Human astaxanthin trials have run 4 to 12 weeks at 4 to 12 milligrams daily and have measured cycling time trial performance, muscle soreness, oxidative stress markers, skin elasticity and eye fatigue, and no human trial has measured lifespan, mortality, frailty or any hard aging endpoint. A safety review of 87 human studies, 35 of which used 12 milligrams daily or more, found no safety concerns, the FDA has granted GRAS status at 6 to 7 milligrams daily, and the main effect reported at sustained high intake is carotenodermia, a reversible orange discoloration of the skin.
What did the Interventions Testing Program find when it tested astaxanthin?
The Interventions Testing Program found that astaxanthin raised median lifespan in male mice by 12 percent and did nothing in females. That is the whole positive result, and it is worth understanding why it carried weight. The Interventions Testing Program is funded by the National Institute on Aging and exists because mouse longevity research has a long history of results that fall apart on closer inspection. It runs every compound simultaneously at three sites, the University of Michigan, the University of Texas Health Science Center at San Antonio, and the Jackson Laboratory, in UM-HET3 mice, a genetically heterogeneous four-way cross bred so that no single inbred quirk can drive an outcome. Compounds are fed in the diet, treatment usually starts in middle age, and the arms run into the hundreds of animals. Very few things pass. In the astaxanthin cohort, treatment began at 12 months of age, the astaxanthin arm held 156 males and 132 females, and the male median lifespan gain of 12 percent came in at p equals 0.003 on a log-rank test. Meclizine, an over-the-counter antihistamine used for motion sickness that also inhibits mTORC1, was tested in the same report and produced an 8 percent male gain at p equals 0.03. Several other compounds in that same report, including fisetin, a hydrogen sulfide donor, dimethyl fumarate, mycophenolic acid and 4-phenylbutyrate, did nothing in either sex. Fisetin failing there is worth noting on its own, because fisetin was at the time one of the most heavily promoted senolytic supplements on the market.
Twelve Percent, in Half of the Mice, Once
Reported median lifespan change against control for every astaxanthin and meclizine arm the NIA Interventions Testing Program has published. In the first cohort, reported in GeroScience after treatment began at 12 months of age, astaxanthin raised male median lifespan by 12 percent at p equals 0.003 and meclizine by 8 percent at p equals 0.03. Neither compound moved female lifespan, with p values of 0.64 and 0.40. Gains at the 90th percentile, shown in amber, were 6 percent for both compounds and reached neither p equals 0.19 nor p equals 0.14 to significance. The replication cohort published in GeroScience in 2026 found no lifespan effect for astaxanthin in either sex. Arms with no statistically significant effect are plotted at zero rather than at their point estimate.
Why did astaxanthin only extend lifespan in male mice?
Nobody knows why astaxanthin worked only in males, but it joined a pattern the Interventions Testing Program has been generating for over a decade. Acarbose extends male median lifespan by roughly 20 percent and female by about 5. 17-alpha-estradiol, a weakly estrogenic steroid, extends male lifespan by roughly 19 percent and does nothing measurable in females. Nordihydroguaiaretic acid is male-specific across a threefold dose range. Canagliflozin produced a male-only gain. Protandim, a botanical Nrf2 activator, produced a male-only gain. Aspirin, in the program's early work, did the same. Astaxanthin and meclizine simply extended the list. The most informative work on why comes from acarbose and 17-alpha-estradiol, where castrating male mice in adulthood before treatment began abolished the male-specific improvements in glucose tolerance and hepatic mTORC2 signaling that accompany the lifespan effect. That points at gonadal hormones sitting somewhere in the causal chain rather than at a simple difference in drug metabolism. It also means the mouse result, if it means anything, means something specifically about males, which is unusual and slightly awkward for a supplement sold to everyone. Astaxanthin is classified as an Nrf2 activator, and Protandim is an Nrf2 activator, and both produced male-only results, which is suggestive without being anything close to a demonstrated mechanism.
The Program Keeps Finding Drugs That Only Work in Males
Approximate median lifespan gains reported by the Interventions Testing Program for six compounds whose effects were larger in males or confined to them. Acarbose is the widest margin at roughly 20 percent in males against about 5 percent in females. 17-alpha-estradiol produced roughly 19 percent in males and nothing measurable in females. Astaxanthin sits in the middle of this group at 12 percent in males. Figures are drawn across different ITP cohorts at the doses each compound was tested and are not directly comparable to one another, so read the pattern rather than the ranking. Castration experiments with 17-alpha-estradiol and acarbose abolished the male-specific metabolic response, which is the strongest evidence that gonadal hormones sit somewhere in the mechanism.
- Male mice
- Female mice
What happened when the Interventions Testing Program tested astaxanthin a second time?
The second time, astaxanthin produced no lifespan extension in either sex. In 2026 the Interventions Testing Program published a report in GeroScience covering eleven compounds under the flat title that astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate and an atorvastatin-telmisartan combination do not increase lifespan in UM-HET3 mice. Astaxanthin and meclizine were in that list because the program was going back to check its own positive findings, this time at different doses and schedules. Neither reproduced. The paper reports that none of the interventions increased lifespan in females in the pooled three-site data or in the two-site subset, and none increased lifespan in males either. There are honest explanations that do not require the first result to have been a false positive. The doses differed between cohorts, and the original astaxanthin arm was itself running at 46 percent of its target concentration, so the two experiments were not testing the same exposure. Diet batches, animal husbandry and cohort-to-cohort variation all shift survival curves. A 12 percent median gain at p equals 0.003 in one cohort is a real number, and a null in the next cohort is also a real number, and the union of the two is a compound whose lifespan effect is not robust. That last sentence is the honest reading, and it is not the sentence anyone selling astaxanthin quotes. It is also worth noting what happened to alpha-ketoglutarate in the same paper, since alpha-ketoglutarate is sold on the strength of a separate set of aging claims and has now been through the program without producing a lifespan effect.
How much astaxanthin were those mice actually eating compared with a supplement capsule?
The mice were eating a human-equivalent dose in the region of 1,600 milligrams a day, and a typical capsule holds 4 to 12. Here is the arithmetic, because this is the part that decides whether the mouse result has any bearing on a person. The delivered concentration was a measured average of 1,840 parts per million in the diet, which is 1.84 milligrams of astaxanthin per gram of food. A mouse of roughly 30 grams eats on the order of 4 grams of chow a day, which puts intake near 7.4 milligrams daily, or roughly 245 milligrams per kilogram of body weight. Converting an animal dose to a human-equivalent dose conventionally divides by a body surface area factor, which for mouse to human is 12.3. That gives about 20 milligrams per kilogram in a person, or roughly 1,600 milligrams a day for an 80 kilogram adult. Body surface area scaling is a regulatory convention rather than a measured equivalence, so the right way to hold that figure is as an order of magnitude and not a prescription. Even allowing generous error, the gap is not close. The most-studied human dose is 12 milligrams. The FDA GRAS designation covers 6 to 7 milligrams. Retail capsules commonly hold 4. The highest single dose reported tolerated in a human study is 48 milligrams, and a gastrointestinal trial has used 40 milligrams daily. Nobody has run a human trial anywhere near the mouse-equivalent exposure, which means nobody knows whether astaxanthin is even absorbed usefully at that level, whether it is tolerable, or whether the carotenodermia that appears above roughly 20 milligrams daily becomes the least of the issues.
The Capsule and the Dose That Produced the Headline
Astaxanthin doses in milligrams per day, placed on one linear axis. The ITP cohort received a measured average of 1,840 parts per million in the diet, which for a 30 gram mouse eating roughly 4 grams of food works out near 240 milligrams per kilogram per day. Converting that to a human-equivalent dose using the standard body surface area factor of 12.3 gives roughly 20 milligrams per kilogram, or on the order of 1,600 milligrams daily for an 80 kilogram adult. Every other bar on this chart is a dose someone has actually swallowed in a study or bought in a shop. The smaller bars are nearly invisible next to the first one, and that is the finding rather than a drafting problem. Body surface area scaling is a rough convention rather than a measured equivalence, so treat the 1,600 milligram figure as an order of magnitude.
What have human astaxanthin trials actually measured?
Human astaxanthin trials have measured exercise recovery, oxidative stress markers, skin appearance and eye fatigue, and none of them has measured aging. The literature is genuinely substantial in volume and genuinely narrow in scope. A 7 day protocol at 12 milligrams daily improved 40 kilometre cycling time trial performance in recreationally trained male cyclists and raised whole-body fat oxidation. A 4 week protocol at the same dose in resistance-trained men reduced subjective delayed onset muscle soreness without producing any measurable gain in strength output, which is a useful illustration of how a real effect can be real and small at the same time. A 4 week trial in people with overweight found that 12 milligrams daily lowered carbohydrate oxidation rate during a graded cycling test without changing fat oxidation. A 28 day trial in young male taekwondo athletes at 12 milligrams reported improvements in specific performance parameters. A meta-analysis of randomized trials found reductions in exercise-induced oxidative stress markers. On the other side, the Xanthin randomized controlled trial in renal transplant patients tested astaxanthin against placebo on arterial stiffness, oxidative stress and inflammation and did not deliver on its primary endpoint. What none of these trials share is a design capable of detecting a change in the rate of aging. They run 4 to 12 weeks in dozens of participants at doses roughly a hundredth of what the mice received, and they report surrogate outcomes. That is not a criticism of the trials, which answered the questions they were built to answer. It is a caution against reading them as human support for a mouse lifespan finding.
What the Human Trials Were Actually Measuring
A schematic map of the human astaxanthin literature. Rose marks outcomes where randomized trials reported a benefit, amber marks results that are real but narrower than they sound, slate marks a trial that missed its primary endpoint, and dark grey marks the studies nobody has run. The human record is built on short trials in athletes, cyclists, resistance-trained men and patients with specific conditions, using 4 to 12 milligrams daily for 4 to 12 weeks. Those trials answer questions about soreness, oxidative stress markers and time trial performance. None of them was designed to detect a change in the rate of aging, and none used a dose in the range that moved mouse lifespan.
How is astaxanthin supposed to work, and does the mechanism support the lifespan claim?
Astaxanthin is described as an Nrf2 activator, and that mechanism is plausible without being sufficient to carry the lifespan claim. Nrf2 is a transcription factor that sits inactive in the cytoplasm under normal conditions and, when oxidative or electrophilic stress releases it, moves into the nucleus and switches on a battery of antioxidant and detoxification genes. Compounds that activate this pathway have a reasonable claim to influencing something aging-relevant, and Nrf2 signaling declines with age in several tissues. Astaxanthin's structure, a long conjugated chain with hydroxyl and keto groups at both ends, lets it sit across a cell membrane rather than dissolving into one face of it, which is the usual explanation for why it behaves differently from beta-carotene. The trouble with mechanism as an argument is that it explains too much. Dimethyl fumarate is one of the most potent Nrf2 activators in clinical use, it is an approved drug for multiple sclerosis, and the Interventions Testing Program tested it in the same report that found the astaxanthin result and it did nothing to lifespan in either sex. Protandim activates Nrf2 and produced a male-only lifespan gain. Astaxanthin activates Nrf2 and produced a male-only lifespan gain that then failed to reproduce. A mechanism that yields three different outcomes across three compounds is not doing much predictive work. Mechanism tells you a claim is not absurd. It does not tell you the claim is true.
Is astaxanthin safe at the doses people actually take?
At the doses people actually take, astaxanthin has one of the cleaner safety records in the supplement aisle. A published safety review examined 87 human studies, 35 of which used 12 milligrams daily or more, and identified no safety concerns. Clinical studies covering more than 2,000 participants have reported good tolerability at 4 to 12 milligrams daily for periods up to a year without serious adverse effects. Natural astaxanthin from Haematococcus pluvialis holds GRAS status in the United States at 6 to 7 milligrams daily. A single 48 milligram dose was tolerated in one study, producing red coloration of the stool from the pigment itself, which is harmless. The one consistently documented effect at sustained intake above roughly 20 milligrams daily is carotenodermia, a reversible orange discoloration of the skin caused by carotenoid deposition in subcutaneous fat, which resolves when intake drops. None of that is a reason to take astaxanthin, and it is important not to let a good safety profile stand in for efficacy. A compound that is cheap and safe and does nothing is still a compound that does nothing. What the safety record does establish is that the downside of a 12 milligram daily habit is small, which is a different and much more modest claim than the one the mouse headline invites. Anyone considering astaxanthin alongside prescribed medication, particularly anticoagulants or drugs metabolised through the same hepatic pathways, should discuss it with a physician rather than reasoning from a supplement label.
What would it take to know whether astaxanthin does anything for human aging?
Knowing whether astaxanthin does anything for human aging would require a trial nobody has funded and probably nobody will. The minimum useful design would randomize adults in middle age or later, run for years rather than weeks, use a dose established by human pharmacokinetics rather than borrowed from a mouse chow concentration, and measure something hard: incident disease, functional decline, frailty, or mortality. Nothing resembling that trial exists. There is not even a dose-ranging study establishing what plasma astaxanthin concentration corresponds to the exposure that moved mouse lifespan, which is the first thing anyone would need before designing the trial. The more realistic near-term question is narrower and more answerable, which is whether the male-specific finding says anything about male physiology worth pursuing. The Interventions Testing Program's male-biased results now form a pattern spanning acarbose, 17-alpha-estradiol, nordihydroguaiaretic acid, canagliflozin, Protandim, meclizine and astaxanthin, and the castration experiments point at gonadal hormones. Whatever is going on there is probably more interesting than any individual compound on the list. For now the honest position on astaxanthin is that it is a safe, inexpensive carotenoid with real but modest effects on exercise recovery markers at 12 milligrams daily, that it produced one striking male mouse lifespan result at a dose roughly a hundred times higher than anyone takes, and that the program which produced that result could not reproduce it. This article is educational and is not medical advice, and astaxanthin is not approved by any regulator to treat, prevent or slow any disease or aging itself.
The Astaxanthin Longevity Record on One Axis
Every strand of the astaxanthin aging case arranged as a single schematic map. Rose marks what the evidence supports, amber marks findings that are real but narrower than the headline suggests, slate marks results that count against the claim, and dark grey marks claims the evidence does not carry. Astaxanthin is a cheap, well-tolerated carotenoid that produced one of the more interesting male lifespan results in the most rigorous mouse aging program running. It is also a compound that the same program then failed to replicate, in males and females alike, and whose retail dose sits about two orders of magnitude below the one that produced the number people quote.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.